Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia

BACKGROUND: Promacta (eltrombopag; EPAG) and Nplate (romiplostim; ROMI) have not been compared in head-to-head trials for treatment of chronic immune thrombocytopenia (cITP); however, indirect treatment comparisons have indicated similar efficacy and safety outcomes, and the drugs are generally acce...

Descripción completa

Detalles Bibliográficos
Autores principales: Patwardhan, Pallavi, Proudman, David, Allen, Jeffrey, Lucas, Sedge, Nellesen, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394751/
https://www.ncbi.nlm.nih.gov/pubmed/34278835
http://dx.doi.org/10.18553/jmcp.2021.21080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394751/
https://www.ncbi.nlm.nih.gov/pubmed/34278835
http://dx.doi.org/10.18553/jmcp.2021.21080

Ejemplares similares